Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,020 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Exploratory Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels

NCT01588561
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine, Saline - placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

NCT02703779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Granulocyte colony-stimulating factor (G-CSF), Mozobil
Drug
Lead sponsor
Siddhartha Ganguly
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 22, 2026, 8:21 PM EDT
Recruiting Phase 2 Interventional

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

NCT06444269
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS)
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Participant Satisfaction With the BUILD Mobile Application

NCT05948670
View directory record Official record
Conditions
Satisfaction, Personal
Interventions
DISC-MVP, DISC-CON
Device
Lead sponsor
Woebot Health
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Treatment With Cetuximab and/or IMC-A12

NCT00957853
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Cetuximab, IMC-A12, Surgical tumor resection
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 22, 2026, 8:21 PM EDT
Suspended Phase 2 Interventional

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

NCT00065572
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
ZD6126, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Los Angeles, California • Newark, Delaware • Tampa, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Canoga Park, California • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

NCT01585402
View directory record Official record
Conditions
Arterial Calcification, CD73 Deficiency
Interventions
Etidronate, MRI Scan
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 22, 2026, 8:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

NCT00577772
View directory record Official record
Conditions
Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions
Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
Drug · Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 22, 2026, 8:21 PM EDT
Recruiting Phase 2 Interventional

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

NCT04661137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 8:21 PM EDT
Completed No phase listed Observational

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

NCT01160536
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
13 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Tenafly, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

NCT02406521
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Pazopanib, Sorafenib, Radium-223
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

NCT01462292
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
GSK2402968 3mg/kg/week, GSK2402968 6 mg/kg/week, Placebo to match GSK2402968 3 mg/kg/week, Placebo to match GSK2402968 6 mg/kg/week
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Gulf Breeze, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 1 Interventional

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

NCT04510298
View directory record Official record
Conditions
Schizophrenia
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Garden Grove, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 22, 2026, 8:21 PM EDT
Suspended Phase 2 Interventional

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

NCT05453799
View directory record Official record
Conditions
Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma
Interventions
Vudalimab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Phase 2 Interventional Results available

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

NCT02872701
View directory record Official record
Conditions
Lung Neoplasms, Lung Cancer
Interventions
OTL38 for Injection, Near infrared camera imaging system, Endoscopic or Thoracic Surgery
Drug · Device · Procedure
Lead sponsor
On Target Laboratories, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Health Disparities in Engagement, Retention, and Utilization of PrEP Among South Florida Women of Color

NCT05338996
View directory record Official record
Conditions
HIV Prevention, PrEP Adherence
Interventions
iENGAGE for PrEP
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Miami, Florida • West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 22, 2026, 8:21 PM EDT
Terminated Phase 2 Interventional

Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma

NCT01011231
View directory record Official record
Conditions
Glioblastoma
Interventions
Gamma Knife Radiosurgery
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 22, 2026, 8:21 PM EDT
Recruiting Not applicable Interventional

Early Detection of Infection Using the Fitbit in Pediatric Surgical Patients

NCT06395636
View directory record Official record
Conditions
Appendectomy, Appendicitis, Appendicitis Acute
Interventions
Infection-Prediction Algorithm
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
3 Years to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Maywood, Illinois • Winfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 22, 2026, 8:21 PM EDT
Terminated Phase 1 Interventional

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

NCT00278434
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Zoledronate, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 22, 2026, 8:21 PM EDT
Completed Not applicable Interventional Results available

Clinical Investigation (Beta) of a New Developed Prosthetic Knee

NCT06748729
View directory record Official record
Conditions
Amputation
Interventions
Navii Knee
Device
Lead sponsor
Össur Iceland ehf
Industry
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 22, 2026, 8:21 PM EDT
Not yet recruiting Phase 4 Interventional

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)

NCT07497620
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
Bimekizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 22, 2026, 8:21 PM EDT